Skip Navigation



Carcinogenesis Advance Access published online on February 18, 2009
Carcinogenesis, doi:10.1093/carcin/bgp039
This Article
Right arrow Advance Access manuscript (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
30/4/655    most recent
bgp039v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Jung, M. H.
Right arrow Articles by Lee, Y. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jung, M. H.
Right arrow Articles by Lee, Y. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR2 signaling pathway

Myung Hwan Jung1, Sun Hee Lee1, Eun-Mi Ahn2 and You Mie Lee1

1 School of Life Sciences and Biotechnology, Department of Natural Sciences, Kyungpook National University, Daegu, 702-701, Korea
2 Department of Herbal Foodceutical Science, Daegu Haany University

Correspondence: You Mie Lee, Ph.D. School of Life Sciences and Biotechnology, Department of Natural Sciences, Kyungpook National University, Daegu, 702-701, Republic of Korea. Tel: +82-53-950-7362, Fax: +82-53-943-6925, E-mail; lym{at}knu.ac.kr

Inhibition of angiogenesis is an attractive approach for the treatment of angiogenic diseases, such as cancer. Vascular endothelial growth factor (VEGF) is one of the most important activators of angiogenesis and interacts with the high affinity tyrosine kinase receptors, VEGFR-1 and VEGFR-2. The pyranocoumarin compounds decursin and decursinol angelate isolated from the herb, Angelica gigas are known to possess potent anti-inflammatory activities. However, little is known about their anti-angiogenic activity or their underlying mechanisms. Here we show the anti-angiogenic effects of decursin and decursinol angelate using in vitro assays and in vivo animal experiments. Decursin and decursinol angelate inhibited VEGF-induced angiogenic processes in vitro, including proliferation, migration and tube formation of human umbilical vein endothelial cells (HUVECs). Decursin and decursinol angelate significantly suppressed neovessel formation in chick chorioallantoic membrane (CAM) and tumor growth in a mouse model. The microvessel density in tumors treated with decursin for 14 days was significantly decreased compared to a vehicle control group. Decursin and decursinol angelate inhibited VEGF-induced phosphorylation of VEGFR-2, extracellular signal-regulated kinases (ERK) and c-Jun N-terminal kinase (JNK) mitogen-activated protein kinases. Taken together, these results demonstrate that decursin and decursinol angelate are novel candidates for inhibition of VEGF-induced angiogenesis.

Key Words: decursin • decursinol angelate • anti-angiogenesis • VEGF • VEGFR2 signaling

Received October 6, 2008; revised January 14, 2009; accepted January 29, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.